<DOC>
	<DOCNO>NCT00320710</DOCNO>
	<brief_summary>Clinical trial breast cancer patient bone metastasis pretreated approximately 1 year standard zoledronic acid regimen . Looking continued effectiveness safety give zoledronic acid every 4 week versus every 12 week give 1 year . This study prospective , double-blind , stratified , multi-center , two-arm .</brief_summary>
	<brief_title>Continued Efficacy Safety Zoledronic Acid ( q 4 Wks vs. q 12 Wks ) 2nd Year Treatment Patients With Bone Metastases From Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Female patient ≥ 18 year age . Confirmed breast cancer bone metastasis . Pretreated Zometa® , Aredia ( pamidronate ) sequential regimen , minimum 9 dos ; Abnormal kidney function determine serum creatinine level . Current active dental problem include : ongoing infection teeth jawbone ; current expose bone mouth ; current prior diagnosis osteonecrosis jaw . Recent ( within 8 week ) plan dental jaw surgery ( e.g. , extraction , implant ) . Diagnosis metabolic bone disease osteoporosis ( e.g. , Paget 's disease bone ) . Known hypersensitivity Zometa . Treatment investigational drug within 30 day prior randomization . Other protocoldefined exclusion criterion may apply .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Breast cancer</keyword>
	<keyword>zoledronic acid</keyword>
	<keyword>bone metastasis</keyword>
</DOC>